

Diagnosis and staging of osteosarcoma

Mayank Shukla^{1*}, Amrta Tiwari², Ankita Kakkar³, Anupama Srivastava⁴

{¹Associate Professor, Department of Orthopaedics} {²Assistant Professor, Department of Pathology}

{³Associate Professor, Department of Forensic Medicine} {⁴Associate Professor, Department of SPM}

Rama Medical College and Research Center, Kanpur, Uttar Pradesh, INDIA.

Email: drmks73@gmail.com

Abstract

Osteosarcoma is a primary malignant tumour of the skeleton characterised by the direct formation of immature bone or osteoid tissue by the tumour cells. The classic osteosarcoma is a rare (0.2% of all malignant tumours), highly malignant tumour, with an estimated incidence of 3 cases/million population/year. Osteosarcoma arises predominantly in the long bones and rarely in the soft tissues. The age at presentation ranges from 10 to 25 years of age. Plain radiographs, computed tomography, magnetic resonance imaging, angiography and dynamic bone scintigraphy are used for diagnosis, evaluation of the extent of tumour involvement and decision of the type of operation and, if necessary, the type of reconstruction. The biopsy confirms the diagnosis and reveals the grade of the tumor. Enneking system for staging malignant musculoskeletal tumors and American Joint Committee on Cancer (AJCC) staging systems are most commonly used for extremity sarcomas. Today, for localised osteosarcoma at onset (80% of cases) treated in specialized bone tumour centres with pre- and postoperative chemotherapy associated with surgery, the percentage of patients cured varies between 60% and 70%. Surgery is conservative (limb salvage) in more than 90% of patients. Prognosis is more severe (cure rate about 30%) for tumours located in the axial skeleton and in patients with metastasis at onset.

Keywords: Osteosarcoma, imaging, biopsy, Enneking staging.

*Address for Correspondence:

Dr. Mayank Shukla, Qtr. No. 102 Staff Accom. Ist, Rama Medical College, Mandhana, Kanpur, Uttar Pradesh, INDIA.

Email: drmks73@gmail.com

Received Date: 17/03/2016 Revised Date: 20/04/2016 Accepted Date: 25/05/2016

Access this article online	
Quick Response Code:	Website: www.statperson.com
	DOI: 01 June 2016

INTRODUCTION

The term “osteosarcoma” as opposed to “osteogenic sarcoma” is preferred by the World Health Organization (WHO). The eponym was introduced by Boyer in 1805¹. In 1879, Gross published a paper entitled “Sarcoma of the Long Bone Based upon a Study of One Hundred and Sixty-five Cases”². Osteosarcoma is defined as the primary malignant mesenchymal bone tumor where the malignant tumor cells directly form the osteoid or bone or both.³⁻¹ Demonstration of osteoid directly formed by the malignant cells in histopathology is essential for making the diagnosis of osteosarcoma.^{4,5} The risk of developing postradiation osteosarcoma correlates with radiation dose

and use of electrophilic chemotherapeutic agents.^{15,16,17} An etiological relationship has not been proven in prosthesis and metal hardware associated osteosarcomas.¹⁸

Epidemiology

Classic osteosarcoma represents approximately 15% of all biopsy-analysed primary bone tumours. Among primary malignant bone tumours, it ranks second in frequency after multiple myelomas. The incidence of classic osteosarcoma is 3 cases/million population/year. It represents 0.2% of all malignant tumours¹⁹.

Etiology

Etiology of osteosarcoma is unknown. A viral origin was suggested by the evidence that bone sarcomas can be induced in selected animals by viruses or cell-free extracts of human osteosarcomas²⁰. The only environmental agent known to cause osteosarcoma in human is ionising radiation²⁰. Radiation is implicated in approximately 2% of osteosarcomas. An increased incidence of radio-induced osteosarcoma is likely to be seen with a longer survival after primary irradiation. Several families have been described with multiple members who developed osteosarcoma, suggesting genetic predisposition to this tumour²¹. So far, the

strongest genetic predisposition is found in patients with hereditary retinoblastoma. In patients with retinoblastoma, osteosarcoma occurs 500 times more frequently than in the general population²². Screening large series of children with osteosarcoma revealed that approximately 3% to 4% carried a constitutional germline mutation in p53²³. The majority of cases with germline p53 mutations represent patients with a family history suggestive of Li-Fraumeni syndrome.

Signs and Symptoms

Most patients who present with osteogenic sarcoma of the extremities complain of pain prior to soft tissue swelling. This is true of any primary bone tumour, because stretching of the periosteum usually causes pain before the tumour is discernible. Pain could also result from

weakening of the bone with development of minute stress fractures. Development of sudden and severe pain heralds gross pathologic fracture, which is an uncommon finding in adult patients. Up to 15% of paediatric patients present a pathological fracture. The second most common complaint is swelling, which is related to the soft tissue mass. Although about 90% of osteosarcoma show soft tissue extension, a few patients complain of swelling. Systemic symptoms as weight loss, pallor, fever, anorexia are very uncommon.

Classification

Osteosarcomas are classified as primary and secondary. Primary are further sub-typed as intramedullary/central and surface osteosarcomas as per World Health Organization classification⁴ [Box 1].

<p>Primary osteosarcomas</p> <p>Conventional-intramedullary/central high grade (most common) further sub-typed as:</p> <ul style="list-style-type: none"> Osteoblastic (50%) Chondroblastic (25%) Fibroblastic (25%) <p>Small cell</p> <p>Telangiectatic</p> <p>Low grade central</p> <p>Surface osteosarcomas:</p> <ul style="list-style-type: none"> Parosteal Periosteal High grade surface <p>Secondary osteosarcomas can occur in Paget's disease and after radiation exposure.^{1,2}</p> <p>Unusual forms of osteosarcoma given below are viewed as subtypes of conventional osteosarcoma because their biological behavior is similar.²</p> <ul style="list-style-type: none"> Osteoblastic osteosarcoma-sclerosing type Osteosarcoma resembling osteoblastoma Chondromyxoid fibroma-like osteosarcoma Chondroblastoma-like osteosarcoma Clear-cell osteosarcoma Malignant fibrous histiocytoma-like osteosarcoma Giant cell rich osteosarcoma Epithelioid osteosarcoma

Box 1: Classification of osteosarcoma

Diagnostic methods

Plain X-ray

The characteristic radiological features are sun-burst appearance, periosteal lifting with formation of Codman's triangle [Figure_1], new bone formation in the soft tissues

along with permeative pattern of destruction of bone and other features for specific types of osteosarcoma^{4,10,24,25}

X-ray chest can detect metastasis in form of cannon ball appearance or nodules in the lungs [Figure_3],




Figure 1: X-ray of humerus anteroposterior view showing osteosarcoma of the proximal humerus- typical sun burst or sun ray appearance, new bone formation in soft tissues, and Codman's triangles (arrows)

Figure 2: Telangiectatic type of osteosarcoma of the proximal tibia: (a) X-ray anteroposterior and lateral views showing lysis and expansion (b) MRI showing fluid levels

Figure 3: Plain X-ray chest of a patient of osteosarcoma showing multiple metastatic lung nodules (b) CT scan (axial section) demonstrating multiple metastases in both lungs.

Computerized tomography scan

CT scan delineates the bony anatomy/architecture like cortical integrity more clearly and picks up pathological fracture and is helpful in assessing ossification and calcification (chondroid component) more accurately^{26,27}

Magnetic resonance imaging

MRI is the most accurate tool for determining the limits of tumor within and outside the bone.^{9,28,29,30}

MRI accurately and precisely delineates (1) extent of the tumor into the soft tissues and the medullary canal, (2) involvement of joint, (3) crossing of the lesion through and/or around the growth plate, (4) any skip lesion in the same bone and across the joint in other bone, (5) proximity and/or encasement of the neurovascular bundle by the tumor.

Radionuclide bone scan

Tc99 methylenediphosphonate (Tc99 MDP) bone scan is the most commonly used investigation for detecting osseous metastasis.

Positron emission tomography


Positron Emission Tomography (PET), which picks up metabolic activity is evolving with tremendous potential in oncology.³¹

Biochemical markers

The role of biochemical markers like serum alkaline phosphatase (ALP) and lactate dehydrogenases (LDH) for diagnosis, prognosis and response to treatment. The response of therapy can be monitored with the levels of these enzymes. High levels after treatment may persist with residual disease or recurrence and in the presence of metastasis.¹⁰

Biopsy

Biopsy should be performed after complete history, clinical examination and imaging. It confirms the diagnosis, reveals specific type and furnishes the grade of the tumor. It is performed by either an open (incisional) or a closed method. Closed biopsy is performed as fine needle aspiration cytology (FNAC) and core needle biopsy.⁹



Classic osteosarcoma in which there is abundant production of osteoid and bone matrix into which the malignant cells are incorporated.

Staging

The common staging systems for malignant bone tumors are: Enneking system for staging malignant musculoskeletal tumors and the American Joint Committee on Cancer (AJCC) System for staging bone sarcomas.⁸

Table 1: Enneking system for staging malignant musculoskeletal tumors

Stage	Grade	Site	Metastasis
IA	Low	Intracompartmental	None
IB	Low	Extracompartmental	None
IIA	High	Intracompartmental	None
IIB	High	Extracompartmental	None
III	Any	Any	Regional or distant metastasis

Table 2: American joint committee on cancer system for staging bone sarcomas

Stage	Grade	Size	Metastasis
I-A	Low	<8 cm	None
I-B	Low	>8 cm	None
II-A	High	<8 cm	None
II-B	High	>8 cm	None
III	Any	Any	Skip metastasis
IV-A	Any	Any	Pulmonary metastasis
IV-B	Any	Any	Nonpulmonary metastasis

CONCLUSION

The plain radiograph provides the best clue to the diagnosis and MRI the local extent. Thorax CT scan and Tc99 bone scan are used for the detection of lung and bony metastasis respectively. The biopsy confirms the diagnosis and reveals the grade of the lesion. The basic principles of biopsy should be followed precisely and meticulously. After clinical, radiological and the histopathological examinations the tumor can be staged adequately.

REFERENCES

1. Boyer, The Lectures Boyer Upon Disease of the Bone, James Humphreys, Philadelphia, Pa, USA, 1805.
2. S. W. Gross, "Sarcoma of the long bones: based on a study of one hundred sixty five cases," The American Journal of the Medical Sciences, pp. 8338–8377, 1879.
3. Rosenberg AE. Robins and cotran pathologic basis of disease. 8th ed. Philadelphia: WB Saunders; 2010. Bone, joints and soft tissue tumors; pp. 1203–56.
4. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. Lyon: IARC Press; 2013. World Health Organization, classification of tumours: Pathology and genetics of tumors of soft tissue and bone.
5. Wold LE, Adler CP, Sim FH, Unni KK. 2nd ed. Philadelphia-London: Saunders; 2003. Atlas of orthopaedic pathology; pp. 179–85.
6. Jaffe HL. Philadelphia: Lea and Febiger; 1958. Tumors and tumors like conditions of the bones and joints.
7. Unni KK. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2010. Inwards CY Bone tumors: General aspects and data on 10,165 cases
8. Lichtenstein L. 4th ed. Mosby: St Louis; 1972. Bone tumors.
9. Heck RK., Jr Canale ST, Beaty JH. Campbell's Operative Orthopedics. Missouri: Mosby Year Book; 2008. Malignant bone tumors; pp. 901–38
10. Dorfman HD, Czerniak B. Mosby: St. Louis; 1998. Bone tumors.
11. Campanacci M. 2nd ed. Vienna: Springer-Verlag; 1999. Bone and soft tissue tumours: Clinical features, imaging, pathology and treatment.
12. Bacci G, Ferrari S, Lari S, Mercuri M, Donati D, Longhi A. Osteosarcoma of the limb: Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg. 2002; 84:88–92.
13. Bacci G, Ferrari S, Longhi A. Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma. J Clin Oncol. 2003; 21:4662–6.
14. Bacci G, Longhi A, Varsari M. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15 years experience in 789 patients treated at a single institution. Cancer. 2006; 106:1154–64.
15. Huvos AG, Woodard HQ, Cahan WG, Higinbotham NL, Stewart FW, Butler A, et al. Postradiation osteogenic sarcoma of bone and soft tissues. A clinicopathologic study of 66 patients. Cancer. 1985; 55:1244–55.
16. Le Vu B, de Vathaire F, Shamsaldin A, Hawkins MM, Grimaud E, Hardiman CA, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumor during childhood. Int J Cancer. 1998; 77:370–7.
17. Tucker MA, D'Angio GJ, Boice JD, Jr, Strong LC, Li FP, Stovall M, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Eng J Med. 1987; 317:588–93.
18. Visuri T, Pulkkinen P, Paavolainen P. Malignant tumors at the site of total hip prosthesis. Analytic review of 46 cases. J Arthroplasty. 2006;21:311–23
19. Campanacci M: Bone and Soft Tissue Tumors: Clinical Features, Imaging, Pathology and Treatment 2nd edition. Wien, Austria: Springer-Verlag; 1999:464-491.

20. Finkel MP, Reilly CA, Biskis BO: Pathogenesis of radiation and virus-induced bone tumors. *Recent Results Cancer Res.* 1976, 92-103.
21. Swaney JJ: Familial osteogenic sarcoma. *Clin Orthop Relat Res.* 1973, 64-68. 10.1097/00003086-197311000-00010. 97
22. Huvos AG: *Bone Tumors: Diagnosis. Treatment and Prognosis* 2nd edition. Philadelphia, W.B. Saunders. Co; 1991.
23. McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen AL, Yan YX, Russo C, Sato J, Barbier N, Miser J: Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. *J Clin Oncol.* 1994, 12 (5): 925-930.
24. Resnick D, Kransdorf MJ. *Bone and joint imaging.* 3rd ed. Philadelphia Pennsylvania: Elsevier Saunders; 2005. *Tumors and tumor-like lesions of bone: Radiographic principles;* pp. 1109–98.
25. Resnick D. *Tumors and tumor-like lesions of bone: Radiographic principles.* In: Resnick D, editor. *Diagnosis of bone and joint disorders.* 4th ed. Philadelphia Pennsylvania: Saunders; 2002. pp. 3745–4128
26. Brown KT, Kattapuram SV, Rosenthal DI. Computed tomography analysis of bone tumors: Patterns of cortical destruction and soft tissue extension. *Skeletal Radiol.* 1986; 15:448–51.
27. Kenney PJ, Gilula LA, Murphy WA. The use of computed tomography to distinguish osteochondroma and chondrosarcoma. *Radiology.* 1981; 139:129–37.
28. Aisen AM, Martel W, Braunstein EM, McMillin KI, Philips WA, Kling TF. MRI and CT evaluation of primary bone and soft-tissue tumors. *Am J Roentgenol.* 1986; 146:749–56.
29. Rubin DA. Magnetic resonance imaging: Practical considerations. In: Resnick D, Kransdorf MJ, editors. *Bone and joint imaging.* 3rd ed. Philadelphia Pennsylvania: Elsevier Saunders; 2005. pp. 118–32.
30. Bohndorf K, Reiser M, Lochner B, Feaux DL, Steinbrich W. Magnetic resonance imaging of primary tumors and tumor-like lesions of bone. *Skeletal Radiol.* 1986;15:511–7
31. Huang TL, Liu RS, Chen TH, Chen WY, Hsu HC, Hsu YC. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma. *J Chin Med Assoc.* 2006; 69:372–6.

Source of Support: None Declared
Conflict of Interest: None Declared